Product Description
For Idiopathic Hypersomnia; BTD-001 is an oral capsule of PTZ (Pentetrazol) (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03542851)
Mechanisms of Action: GABA Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Balance
Company Location: MIAMI FL 33139
Company CEO: Michael D. Farkas
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Hypersomnolence, Idiopathic|Disorders of Excessive Somnolence|Narcolepsy|Cataplexy
Phase 1: Healthy Volunteers|Down Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| The COMPOSE Study | P1 |
Completed |
Down Syndrome |
2015-01-27 |
|
| None | P1 |
Completed |
Healthy Volunteers |
2013-08-16 |
|
| BTD-001 IH201 | P2 |
Completed |
Narcolepsy|Cataplexy|Hypersomnolence, Idiopathic|Disorders of Excessive Somnolence |
2018-02-01 |
|
| HV103 | P1 |
Completed |
Healthy Volunteers |
2017-05-01 |
|
| BTD-001 HV104 | P1 |
Completed |
Healthy Volunteers |
2017-07-12 |